News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
During the program, Kamna Giare-Patel, CEO of Cerespectus and Thomas H., CEO of Peroxitech, shared their startup journeys and discussed their companies.
According to the report, Penn ranked within the top five largest research & development expenditures of US universities in 2021.
ViTToria is focused on developing novel CAR-T cell therapies that transcend the limitations of current cell therapies.
The Office of the Vice Provost for Research has provided nearly $1 million in funding to support research through Discovering the Future and Accelerating From Lab to Market research grant programs.
“One of our great strategic advantages is our compact and contiguous campus, where 12 amazing schools and a world-class health system coexist just a short walk from one another,” said Magill.
Penn spinout Vivodyne closed a $38 million seed funding round led by Khosla Ventures.
The goal of this platform is to engineer adoptive cell therapies inside of the body for specific autoimmune diseases.
The company plans to initiate a Phase 1/2 clinical trial of CABA-201 in two cohorts of patients with generalized myasthenia gravis (gMG).
Heirloom uses a process called direct air capture to remove greenhouse gases from the atmosphere.
Vetigenics announced that the first canine patient has received his first dose of Vetigenics' fully canine anti-CTLA4 monoclonal antibody (VGS-001) for oral melanoma.